名字 发表于 2025-3-28 15:20:53

http://reply.papertrans.cn/25/2415/241423/241423_41.png

mastopexy 发表于 2025-3-28 21:22:23

http://reply.papertrans.cn/25/2415/241423/241423_42.png

草率男 发表于 2025-3-28 23:18:39

MicroRNAs in FECD: A New Therapeutic Option?,ongenital cataract, and stromal thinning (EDICT syndrome). Improved understanding of the role of miRNAs in physiological and pathological conditions of the corneal endothelium may provide us with new strategies to treat corneal endothelial diseases.

灿烂 发表于 2025-3-29 05:18:17

http://reply.papertrans.cn/25/2415/241423/241423_44.png

迅速飞过 发表于 2025-3-29 08:27:57

http://reply.papertrans.cn/25/2415/241423/241423_45.png

没有贫穷 发表于 2025-3-29 14:09:38

http://reply.papertrans.cn/25/2415/241423/241423_46.png

形状 发表于 2025-3-29 19:30:41

Die Verarbeitung der Kali-Endlauge,h more predictable refractive outcome, reduced risk of immunological rejection, and many more advantages over DSEK and PK. It is a surgery which is readily accessible to any cornea surgeon in any ophthalmology setup. A structured approach with careful attention to the key elements will help ensure success.

狂怒 发表于 2025-3-29 22:29:54

http://reply.papertrans.cn/25/2415/241423/241423_48.png

航海太平洋 发表于 2025-3-30 03:43:33

http://reply.papertrans.cn/25/2415/241423/241423_49.png

只有 发表于 2025-3-30 05:33:10

http://reply.papertrans.cn/25/2415/241423/241423_50.png
页: 1 2 3 4 [5] 6
查看完整版本: Titlebook: Current Treatment Options for Fuchs Endothelial Dystrophy; Claus Cursiefen,Albert S. Jun Book 2017 Springer International Publishing Switz